CMV Reactivation: Causes, Symptoms, and Treatment

Cytomegalovirus reactivation happens when a virus that has been silently hiding in your body’s blood-forming stem cells wakes up and begins copying itself again, typically because your immune system has been weakened by illness, medication, or major physiological stress. The initial CMV infection is almost always symptomless in healthy people, and the virus then persists for life in a dormant state. Most adults carry it: global seroprevalence ranges from roughly 40% in some high-income countries to above 95% in parts of Latin America and Africa.¹ Reactivation is rarely a problem when your immune defenses are intact, but it becomes a serious medical concern after organ transplants, during HIV/AIDS, in critical illness, and in other situations where the immune system cannot keep the virus in check.

How CMV Hides and What Wakes It Up

After your first encounter with CMV, the virus takes up permanent residence in a specific type of cell: CD34+ hematopoietic progenitor cells, the precursors that eventually become your white blood cells. The virus enters these cells through a process called macropinocytosis, essentially tricking the cell into swallowing it. Once inside, CMV deliberately fails to fully unpack its genetic cargo, which keeps the cell from recognizing the virus as a threat and allows it to settle into a quiet, latent state.² This latency is lifelong. The virus sits in myeloid lineage cells, producing minimal viral activity, waiting.³

What flips the switch from dormancy to active replication? Researchers have identified several molecular triggers that can work alone or together: oxidative stress, DNA damage within host cells, and inflammatory signaling molecules called cytokines.⁴ One of the best-studied triggers is tumor necrosis factor alpha (TNF-α), a cytokine your body releases in large amounts during infection and inflammation. TNF-α can kick-start CMV’s gene activity independently of whether the host cell has matured, meaning the virus does not need to wait for the progenitor cell to develop into a mature immune cell before reactivating.⁵ This is a cruel irony: the very inflammatory response your body mounts against another infection can awaken CMV from its hiding place.

Who Is Most at Risk

The people most vulnerable to clinically significant CMV reactivation fall into a few broad groups, and the stakes differ depending on the setting.

Transplant Recipients

Organ and stem cell transplant recipients face the highest risk because they take immunosuppressive drugs to prevent their body from rejecting the graft. In one cohort of allogeneic hematopoietic stem cell transplant recipients, CMV reactivated in about 63% of patients, with a median onset around 33 days after transplant. Risk factors included mismatched donors and graft-versus-host disease (GVHD), which nearly tripled the odds of reactivation.⁶ The relationship between GVHD and CMV runs in both directions: CMV reactivation independently increases the subsequent risk of GVHD, and GVHD independently increases the risk of CMV reactivation, creating a damaging feedback loop.⁷

In solid organ transplant recipients, CMV reactivation raises the risk of acute graft rejection across multiple organ types. A meta-analysis of 27 studies covering more than 6,300 patients found that those with CMV infection had roughly double the odds of acute rejection compared with CMV-negative recipients, with liver transplant recipients facing the steepest increase.⁸ The threat extends beyond rejection alone. CMV’s indirect effects in transplant patients include chronic graft dysfunction, cardiovascular complications, post-transplant diabetes, and greater susceptibility to secondary bacterial and fungal infections.⁹

People Living with HIV

Before effective antiretroviral therapy was widespread, CMV retinitis was one of the most feared opportunistic infections in people with advanced HIV. It remains a threat in settings where access to care is limited. A study in northern Thailand found that for every 10-cell drop in CD4 count, the odds of CMV retinitis increased by about 40%.¹⁰ Beyond the eyes, the most common neurological manifestation of CMV disease in HIV is retinitis itself, followed by encephalitis and nerve damage in the lower spine and limbs.¹¹

Critically Ill Patients in Intensive Care

CMV reactivation is not limited to classically immunocompromised people. It also occurs in otherwise healthy individuals who land in the ICU with severe infections. In patients already carrying latent CMV who develop severe sepsis, reactivation has been observed in roughly 41% of cases. While it did not raise mortality in the study that tracked it, reactivation was independently associated with a tripling of ICU length of stay and prolonged time on mechanical ventilation.¹² The pattern of higher infection rates in seropositive ICU patients confirms that reactivation of latent virus, rather than new infection, is the primary mechanism at work in the critical care setting.¹³

What Reactivation Looks and Feels Like

CMV reactivation can be completely silent on blood tests without causing any symptoms, or it can progress to full-blown CMV disease affecting specific organs. The clinical picture depends on which organ the virus targets and how weakened the immune system is.

When the gastrointestinal tract is involved, CMV colitis typically causes loose stools, bloody stool, and weight loss. It can also appear in people with underlying inflammatory bowel disease who were not previously known to have it, complicating the diagnostic picture.¹⁴ CMV pneumonitis causes cough, breathlessness, and fever, and is particularly dangerous in lung transplant recipients. CMV hepatitis presents with elevated liver enzymes and sometimes jaundice. In advanced HIV, CMV retinitis can cause blurred vision, floaters, and eventually blindness if untreated. Encephalitis, while less common, leads to confusion, seizures, and cognitive decline.

The challenge is that none of these symptoms are unique to CMV. Fever, fatigue, and organ-specific complaints overlap with dozens of other infections and with graft rejection itself. That overlap is why laboratory diagnosis matters so much.

How Reactivation Is Detected

The standard tool for identifying CMV reactivation is a quantitative PCR blood test that measures how much viral DNA is circulating in your plasma. This test is performed routinely, sometimes weekly, in transplant patients during the highest-risk window after surgery. PCR-based viral load measurement is accurate and precise within a given laboratory, though standardization between different labs has been a longstanding issue since each may use a slightly different assay with different calibration.¹⁵ An international standard has since been introduced to improve comparability, but you should know that the specific copy-number thresholds used to trigger treatment can still vary between transplant centers.

Even low levels of detectable CMV DNA carry clinical meaning. Research has shown that when viral DNA first appears at low copy numbers, the viral load frequently continues to climb on subsequent tests, or the clinical team initiates antiviral treatment in response to the rising trend.¹⁶ That is why serial monitoring, rather than a single snapshot, is the backbone of CMV surveillance.

When CMV disease involves a specific organ, tissue biopsy can confirm the diagnosis. Pathologists look for characteristic “owl’s eye” inclusion bodies in tissue samples. Finding them is highly specific for CMV, meaning false positives are rare, but the method is not very sensitive, so a negative biopsy does not rule out CMV involvement.¹⁷ For gastrointestinal disease specifically, immunohistochemistry staining on biopsy tissue is considered the gold standard because it picks up more cases than standard tissue staining alone.¹⁸

Antiviral Treatment

The first-line drugs for CMV reactivation are ganciclovir (given intravenously) and its oral prodrug valganciclovir. Both work by the same mechanism: once inside an infected cell, the drug gets converted into an active form that mimics one of the building blocks of DNA. The viral DNA-copying machinery incorporates this fake building block, which then halts the growing DNA chain and stops the virus from replicating.¹⁹ The main downside is bone marrow toxicity. Ganciclovir and valganciclovir can suppress production of white blood cells, red blood cells, and platelets, which is an especially unwelcome side effect in transplant recipients who may already have fragile blood counts.

When ganciclovir-based therapy fails or is not tolerated, second-line options include foscarnet, which directly blocks the viral DNA polymerase without needing to be activated by the virus first, and cidofovir, another nucleotide analogue. Both have significant toxicity profiles, particularly kidney damage with foscarnet and cidofovir. More recently, two newer agents have expanded the toolbox. Letermovir works through a different viral target (the terminase complex that packages viral DNA) and is approved for prophylaxis in stem cell transplant recipients. Maribavir inhibits a viral kinase and is approved specifically for treating CMV infection that has not responded to other drugs.²⁰

Drug Resistance

Prolonged antiviral treatment, especially in the setting of ongoing immunosuppression, creates conditions for the virus to develop resistance. Resistance typically shows up after extended ganciclovir use and is diagnosed by finding specific mutations in two viral genes: UL97, which encodes the kinase that activates ganciclovir inside the cell, and UL54, which encodes the viral DNA polymerase that the drug targets. Most ganciclovir-resistant strains carry one of a handful of well-characterized UL97 mutations.²¹

The problem can compound over time. When a patient’s virus develops ganciclovir resistance and the treatment is switched to foscarnet or cidofovir, additional mutations in UL54 may emerge that confer resistance to the new drug as well. Deep sequencing has revealed that resistant subpopulations of virus can appear and sometimes vanish during treatment, making resistance a moving target.²² In a study of patients with refractory CMV infection, antiviral-resistant mutations were found in about 27% of cases, and some individual mutations conferred high-level resistance to all three conventional drugs simultaneously.²³ Rates of resistant CMV in solid organ transplant recipients treated for the virus have been reported at up to 18%.²⁰

Prophylaxis Versus Preemptive Therapy

Transplant centers use two main strategies to prevent CMV disease. Universal prophylaxis means giving every high-risk patient antiviral medication starting right after transplant and continuing for a set period, usually three to six months. Preemptive therapy means monitoring the patient’s blood regularly with PCR and starting antivirals only when virus is actually detected. Each approach has trade-offs, and the evidence does not clearly favor one for all situations.

A systematic review and meta-analysis of randomized trials found that universal prophylaxis reduced the likelihood of detecting CMV in the blood compared with preemptive therapy, but the rates of actual CMV disease were not significantly different between the two approaches. Prophylaxis also came with a higher incidence of late-onset CMV disease, appearing after the prophylactic medication was stopped, and was associated with a greater risk of acute kidney injury.²⁴ A randomized trial in high-risk liver transplant recipients (donor-positive, recipient-negative) found that CMV disease was actually lower in the preemptive group, at 9% versus 19% with prophylaxis.²⁵

On the other hand, a renal transplant trial comparing preemptive valganciclovir with valacyclovir prophylaxis found similar rates of CMV disease but a significantly higher rate of biopsy-proven acute rejection in the preemptive group, roughly 36% versus 15%.²⁶ The takeaway is that neither strategy is universally superior. The choice depends on the organ transplanted, the donor-recipient CMV serostatus, and the specific drugs and monitoring infrastructure available at the transplant center.

Adoptive T Cell Therapy for Refractory Infections

When antivirals fail and drug resistance narrows the options, an entirely different approach has gained traction: infusing the patient with T cells that have been selected or expanded to specifically target CMV. The logic is straightforward. If the patient’s own immune system cannot control the virus because of immunosuppression, you can give it a boost by transferring virus-specific T cells from a donor or from the patient’s own stored blood.

One early case report described a lung transplant recipient with ganciclovir-resistant CMV pneumonia who was on mechanical ventilation. After receiving an infusion of his own CMV-specific T cells, the viral load dropped and the patient recovered enough to leave the hospital. The infection later recurred at a lower level, likely because the transferred T cells were late-stage cells that did not persist long in the body.²⁷ Newer research has explored using gamma-delta T cells, a less conventional arm of the immune system, to treat refractory CMV. Preclinical transplant models have shown that CMV-reactive gamma-delta T cells can be generated even from kidney transplant patients with active refractory infections and that they retain their antiviral function despite immunosuppressive drugs.²⁸ This approach is still largely experimental, but it represents a fundamentally different way to tackle the problem when drugs alone are not enough.

CMV Reactivation During Pregnancy

Pregnant women who already carry latent CMV can experience non-primary reactivation during pregnancy, and this is surprisingly common. In one prospective study, about 42% of seropositive pregnant women showed evidence of non-primary CMV infection during their pregnancy. The reassuring finding, however, was that none of those women transmitted the virus to their baby, placing the estimated transmission rate at no more than about 3.5%.²⁹ This stands in contrast to primary CMV infection (a first-time infection during pregnancy), which carries a much higher risk of congenital transmission and can lead to hearing loss, developmental delays, and other problems in the newborn. The pre-existing immune memory from a previous infection appears to provide substantial, though not absolute, protection for the fetus.³⁰

Psychological Stress and Subclinical Reactivation

You do not have to be a transplant patient or have HIV for CMV to stir. There is a body of research linking everyday psychological stress to signs of low-level CMV reactivation in otherwise healthy people. In a large occupational study of CMV-seropositive adults, higher levels of anxiety, depression, and vital exhaustion were all associated with elevated CMV antibody levels, a proxy for increased viral activity. Lower mental health scores tracked consistently with higher antibody titers.³¹ The direction of causation is tricky to untangle: stress may promote viral reactivation, or subclinical viral reactivation may contribute to feeling unwell, or both could share a common driver. What the data do show is a reliable statistical link, even after adjusting for age, sex, and other confounders.

CMV, Immune Aging, and Memory Inflation

Over a lifetime of keeping CMV in check, your immune system pays a cumulative cost. Controlling the virus requires a large and growing army of CMV-specific CD8+ T cells, a phenomenon researchers call “memory inflation.” These virus-specific cells progressively expand and can eventually dominate a substantial fraction of the total T cell pool, particularly in older adults. The inflated CMV-specific T cells tend to resemble exhausted, late-stage cells with limited ability to respond to new threats.³² This phenomenon has led to considerable interest in whether lifelong CMV carriage contributes to the general decline in immune function seen with aging. The idea is that the immune system becomes so preoccupied with policing CMV that it has fewer resources to deal with other infections, respond to vaccines, or perform immune surveillance. The research is ongoing, but the sheer scale of the immune commitment to CMV control is striking and sets it apart from most other chronic viral infections.

The Vaccine Landscape

There is currently no licensed vaccine against CMV, despite decades of effort. A CMV vaccine has been called one of the highest priorities in vaccine development because of the burden of congenital CMV disease and the costs of managing post-transplant infections. The most advanced candidates use mRNA technology. One investigational vaccine, mRNA-1647, encodes two CMV surface proteins (glycoprotein B and the pentameric glycoprotein complex) and has been tested in Phase 2 trials.³³ Preclinical work comparing mRNA-based vaccines with older protein-adjuvant formulations found that the mRNA approach produced antibody responses with greater durability and broader coverage of different viral surface targets.³⁴ Whether these vaccines can prevent primary infection, reduce reactivation events, or both remains to be determined in larger efficacy trials. If a vaccine does eventually reach the market, it could reshape how transplant medicine and congenital infection prevention work from the ground up.

Interactions with Other Herpesviruses

CMV is one of several herpesviruses that can reactivate in immunocompromised patients, and these viruses do not always behave independently. After allogeneic stem cell transplant, reactivation of human herpesvirus 6 (HHV-6) has been linked to concurrent CMV reactivation.³⁵ The clinical significance of these co-reactivations is not fully sorted out, but the pattern suggests that when the immune system is disrupted enough for one herpesvirus to reactivate, conditions are often ripe for others to follow. Clinicians managing transplant patients tend to monitor for multiple viruses simultaneously for this reason. Whether treating one viral reactivation affects the course of another is an area where the evidence is still thin, but the coexistence of these events complicates management and can compound immune recovery challenges.